X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs NOVARTIS - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA NOVARTIS GLENMARK PHARMA/
NOVARTIS
 
P/E (TTM) x 16.7 265.8 6.3% View Chart
P/BV x 3.0 22.6 13.4% View Chart
Dividend Yield % 0.4 1.6 24.7%  

Financials

 GLENMARK PHARMA   NOVARTIS
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
NOVARTIS
Mar-17
GLENMARK PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs993855 116.1%   
Low Rs729666 109.6%   
Sales per share (Unadj.) Rs325.5219.0 148.6%  
Earnings per share (Unadj.) Rs39.319.1 205.7%  
Cash flow per share (Unadj.) Rs48.720.3 239.8%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.21.3 17.7%  
Book value per share (Unadj.) Rs159.2307.0 51.9%  
Shares outstanding (eoy) m282.1729.96 941.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.63.5 76.2%   
Avg P/E ratio x21.939.8 55.1%  
P/CF ratio (eoy) x17.737.5 47.2%  
Price / Book Value ratio x5.42.5 218.4%  
Dividend payout %5.152.4 9.7%   
Avg Mkt Cap Rs m242,99122,779 1,066.8%   
No. of employees `00013.00.7 1,923.9%   
Total wages/salary Rs m16,4081,393 1,177.9%   
Avg. sales/employee Rs Th7,083.99,736.2 72.8%   
Avg. wages/employee Rs Th1,265.42,066.8 61.2%   
Avg. net profit/employee Rs Th855.1849.0 100.7%   
INCOME DATA
Net Sales Rs m91,8576,562 1,399.8%  
Other income Rs m374702 53.3%   
Total revenues Rs m92,2307,264 1,269.7%   
Gross profit Rs m20,367259 7,866.8%  
Depreciation Rs m2,64436 7,364.1%   
Interest Rs m2,3737 32,961.1%   
Profit before tax Rs m15,724917 1,714.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,827345 1,108.9%   
Profit after tax Rs m11,088572 1,937.7%  
Gross profit margin %22.23.9 562.0%  
Effective tax rate %24.337.6 64.7%   
Net profit margin %12.18.7 138.4%  
BALANCE SHEET DATA
Current assets Rs m68,7469,731 706.4%   
Current liabilities Rs m27,0271,830 1,476.6%   
Net working cap to sales %45.4120.4 37.7%  
Current ratio x2.55.3 47.8%  
Inventory Days Days8549 174.6%  
Debtors Days Days9625 379.8%  
Net fixed assets Rs m24,13257 42,189.6%   
Share capital Rs m282141 200.6%   
"Free" reserves Rs m44,6439,056 493.0%   
Net worth Rs m44,9259,196 488.5%   
Long term debt Rs m45,3630-   
Total assets Rs m117,63911,499 1,023.0%  
Interest coverage x7.6128.4 5.9%   
Debt to equity ratio x1.00-  
Sales to assets ratio x0.80.6 136.8%   
Return on assets %11.45.0 227.1%  
Return on equity %24.76.2 396.7%  
Return on capital %19.110.1 190.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,152129 43,562.1%   
Fx outflow Rs m8,0841,734 466.2%   
Net fx Rs m48,068-1,605 -2,994.9%   
CASH FLOW
From Operations Rs m6,574-380 -1,732.4%  
From Investments Rs m-7,1244,208 -169.3%  
From Financial Activity Rs m5,432-3,318 -163.7%  
Net Cashflow Rs m1,992510 390.6%  

Share Holding

Indian Promoters % 48.3 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 6.9 2.0 345.0%  
FIIs % 34.4 1.6 2,150.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 21.5 48.8%  
Shareholders   56,727 41,647 136.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   SANOFI INDIA  ASTRAZENECA PHARMA  STRIDES SHASUN LTD  STERLING BIOTECH  JUBILANT LIFE SCIENCES  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Cheap Valuation of PSU Banks and Key Stocks in Action Today(Pre-Open)

NSE PSU Bank Index surged 30% on 25th October 2017-the date when bank recapitalization of Rs 2.1 trillion was announced.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Looking Beyond the Colourful Prism of This Airline Company(Sector Info)

May 10, 2018

Can Interglobe Aviation Safely Fly Out of Turbulence?

HDFC Prudence Fund Now HDFC Balanced Advantage Fund - Time To Sell?(Outside View)

May 9, 2018

PersonalFN provides detail analysis on HDFC Balanced Advantage Fund (erstwhile HDFC Prudence Fund and HDFC Growth Fund).

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


May 18, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS